Genzyme to Market Elaprase in Japan (Japan)
This article was originally published in PharmAsia News
Executive Summary
Genzyme Corp. has gotten approval from the Japanese government to begin distributing Elaprase in Japan. As part of a deal with Shire Human Genetic Therapies, Genzyme will market Elaprase in Asia. In addition to Japan, Genzyme expects to receive approval for the drug in Australia by the end of 2007, as well as Taiwan and South Korea in 2008. Elaprase is used to treat patients with Hunter syndrome, a rare genetic disorder that causes severe and eventually fatal damage to tissues and organs. Genzyme has been doing business in Japan for 20 years and currently has about 100 employees working in the country. Elaprase is the fifth enzyme replacement therapy the company has introduced there. (Click here for more